16 / 42
Response Rates and Drug Exposure
CR, complete response; PR, partial response; SD, stable disease.
TC2/3 or IC2/3 = TC or IC ≥ 5% PD-L1–expressing cells, respectively;
TC3 or IC3 = TC ≥ 50% or IC ≥ 10% PD-L1–expressing cells; TC2 or IC2 = TC2/3 or IC2/3 excluding TC3 or IC3.
Investigator assessment. Error bars correspond to 95% CIs.
Data cutoff date: August 7, 2017.
Carcereny et al., BIRCH. WCLC 2017
16
Atezolizumab
Exposure
Mean (SD)
Treatment duration, mo
9.8 (10.8)
Dose intensity, %
98.5 (7.0)
No. of doses
14.6 (15.1)
0
20
40
60
80
100
CR/PR
SD
TC2/3 or IC2/3
TC3 or IC3
TC2 or IC2
Frequency, %
n = 23
n = 36
n = 13
n = 21
n = 57
n = 36
32%
35%
26%
41%
18%
49%